Collplant Biotechnologies Ltd. · NASDAQ:CLGN
Collplant Biotechnologies — HCW Global Investment Conference September 2019
23 slides from Collplant Biotechnologies's conference presentation, Sep 9, 2019
Slide 1: CollPlant Overview
CollPlant Overview HCW Global Investment Conference September 2019
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements in this presentation constitute "forward - looking statements" within the meaning of Section 27 A of the Securities Act and Section 21 E of the Securities Exchange Act and are usually identified by the use of words such as "anticipates," "believes," "estimate
Slide 3: Overview
O v e r view ● Deep Tech * company developing, manufacturing and commercializing regenerative medicine products ● Proprietary technology platform that enables mass production of recombinant human collagen (rhCollagen) ● rhCollagen - based products aimed at 3D Bioprinting of tissues and organs, and m
Slide 4: Experienced management team
Prof. Oded Shoseyov Co - Founder & Chief Scientist Pauli Clean Tech CBD Tech. F u l cru m - SPD Melodea Hebrew University Eran Rotem Deputy CEO & CFO Tefron, CFO (NYSE,TASE) Healthcare Tech., CFO (NASDAQ) & Gamida E&Y Ilana Belzer, PhD COO BioHarvest Procognia Ltd. Omrix Biopharmaceuticals Interphar
Slide 5: CollPlant's technology
CollPlant’s technology Co - expression of 5 human genes in tobacco plants for the production of functional type I human recombinant Collagen 5 P 4 Hα P 4 Hβ LH - 3 Post translational modifications Co l 1α 1 Co l 1α 2 Stable production in tobacco plant Structural genes Enzyme genes Tobacco plant Toba
Slide 6: Plant-derived rhCollagen: the ideal building block for regenerative medicine
Plant - derived rhCollagen The ideal building block for regenerative medicine 6 Animal - derived Cell binding domains Cell binding domains Few cell binding domains due to partially denatured crosslinked collagen Many cell binding domains enabled by perfect triple helix enhance cellular attachment Sl
Slide 7: Medical aesthetics: regenerative dermal filler
Medical ae s th e tics R e g ene r a t i v e dermal filler
Slide 8: Dermal fillers market overview
Dermal fillers market overview ~2,091,476 HA procedures in 2017 in the US 1 Global dermal filler market, 2017 2 Cost per syringe: $100 - $250/unit 3 9% 0% 3% 78% 5% 1% 4% Calcium Hydroxylapatite Collagen Fat Hyaluronic acid Polylactic acid Polymethyl methacrylate microsphares PRP 2017 Procedure brea
Slide 9: Combining the advantages of Collagen and Hyaluronic Acid
HA Physical properties • Highly viscous: Provides mechanical stability after injection • Convenient injection: 37 - 32G needle, 10 - 15N expression force • High lifting capacity • Transparent Combining the advantages of Collagen and Hyaluronic Acid 9 rhCollagen Biological properties • Promotes cell
Slide 10: Photocurable rhCollagen-HA regenerative dermal filler
Photocurable rhCollagen - HA regenerative dermal filler Good tissue retention Sculpturing before curing Easy injection (30G needle) I n je c tion Scul p turing Photocuring in - situ Optimized post curing stiffness 10
Slide 11: 3D Bioprinting tissues & organs
3D Bioprinting tissues & organs
Slide 12: Organ transplantations are expensive and inefficient
Organ transplantations are expensive and inefficient Grand Challenges of Organ Banking: Proceedings from the first global summit on complex tissue cryopreservation, Cryobiology, Volume 72, April 2016, Pages 169 - 182. 12 Average transplant costs and wait times in USA: The advent of 3D bioprinting is
Slide 13: 3D bioprinting major market segments
3D bioprinting major market segments • Lungs • Liver • Kid n e y • Heart O r g ans • Ovary • P a nc r eas • Thyroid Scaffolds • Spine fusion • Non - union fractures • Craniomaxillofacial • Nerve conduits • Tendons & ligaments Endocrine glands 1 In the U.S, total number - Lewis JK, Bischof JC, Brasla
Slide 14: BioInk for 3D printing of tissues and organs
BioInk for 3D printing of tissues and organs CollPlant’s rhCollagen - based BioInk offers ideal characteristics for 3D bioprinting 14 Optimal rheology at room temperature - Viscosity and gelation kinetics Non immunogenic, excellent safety profile in clinical use (rhCollagen) Biocompatible – supports
Slide 15: Collaboration agreement with United Therapeutics
15 Collaboration agreement with United Therapeutics (Oct. 2018) • Global licensing and commercialization agreement for 3D Bioprinting of solid organ scaffolds for human transplants • Collaboration combines CollPlant’s proprietary BioInk technology and United Therapeutics’ regenerative medicine and o
Slide 16: 3D bioprinting of trachea and bronchi
16 3D bioprinting of trachea and bronchi Courtesy of United Therapeutics 100µ perfused vessels
Slide 17: Breast implants
Breast impla n ts
Slide 18: Breast implants market overview
60 % 21 % 19 % Breast implants market overview Cost $ 5 - 10K per procedure in US 2 ~2,500,000 Breast implant procedures WW (2017) 4 ~500,000 in US (2018) 5 Market $1.4B worldwide (2018) 1 Current breast reconstruction is based on synthetic breast implantation, free flap surgery/autologous fat tissu
Slide 19: CollPlant's 3D bioprinted breast implants
19 CollPlant’s 3D bioprinted breast implants Breast scaffold printing Loading ECM components + autologous fat cells Implantation and vascularization Implant replacement by newly formed tissue
Slide 20: NASDAQ (CLGN) listed ADR since Jan. 2018
20 NASDAQ (CLGN) listed ADR since Jan. 2018 Market Cap of ~ $16M * 45 employees • Strong R&D team • Fully integrated • Production team with eight years track record * As of August 30, 2019
Slide 21: Planned milestones
Planned 12 - month milestones ● Medical aesthetics - Sign collaboration agreement with strategic partner - Photocurable dermal filler animal study ● 3D Bioprinting - Expand collaborations with key players - Breast implants animal study 21
Slide 22: CollPlant investment highlights
CollPlant investment highlights Only commercially viable technology currently available that can produce truly human collagen Multi - billion dollar market: innovative rhCollagen products initially aimed at 3D bioprinting and medical aesthetics Broadly applicable technology: Ideal building block/sca
Slide 23: Thank you
p C 0 | | Pp | q nt Pioneering Regenerative >> Medicine ~ Thank you
CollPlant Biotechnologies — HCW Global Investment Conference September 2019 on 6ix